Stock analysis, AI verdict, fundamentals & technical signals
Rating: NEUTRAL
Price: $1.81 Analyst target: $8.88 Upside: 390.61%
Pyxis Oncology, Inc., a preclinical biotechnology company, is dedicated to developing antibody-drug conjugate (ADC) and monoclonal antibody (mAb) immunotherapies for treating cancers. The company is headquartered in Cambridge, Massachusetts.
See the full interactive analysis & chart →Informational only — not investment advice.